Table of Contents

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 4, 2010

 

 

MOLECULAR INSIGHT

PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in Charter)

 

 

 

Massachusetts   001-33284   04-0562086

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

160 Second Street, Cambridge, Massachusetts 02142

(Address of Principal Executive Offices, Including Zip Code)

(617) 492-5554

(Registrant’s Telephone Number, Including Area Code)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

Table of Contents

 

TABLE OF CONTENTS

 

Item 2.02. Results of Operations and Financial Condition      3   
Item 9.01. Financial Statements and Exhibits      3   
SIGNATURES      4   
EX-99.1 Press Release of Molecular Insight Pharmaceuticals, Inc. dated November 4, 2010   

Table of Contents

 

Item 2.02. Results of Operations and Financial Condition.

On November 4, 2010, Molecular Insight Pharmaceuticals, Inc. (the “Company”) issued a press release announcing the financial results of the Company for the three and nine months ended September 30, 2010, as well as certain operational updates. A copy of the press release is furnished with this report as Exhibit 99.1 to this Form 8-K.

Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities under that section, nor shall it be deemed incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits. The following exhibit is furnished pursuant to Item 2.02:

 

99.1    Press Release of Molecular Insight Pharmaceuticals, Inc. dated November 4, 2010.

 

3

Table of Contents

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, hereunto duly authorized, on the 4th day of November, 2010.

 

MOLECULAR INSIGHT PHARMACEUTICALS, INC.
By:   / S /    C HARLES H. A BDALIAN , J R .        
Name:   Charles H. Abdalian, Jr.
Title:   Chief Financial Officer

 

4

Table of Contents

 

Exhibit Index to Current Report on Form 8-K

 

Exhibit
Number

    
99.1    Press Release of Molecular Insight Pharmaceuticals, Inc. dated November 4, 2010

 

5

Molecular Insight Pharmaceuticals (MM) (NASDAQ:MIPI)
Gráfico Histórico do Ativo
De Out 2024 até Nov 2024 Click aqui para mais gráficos Molecular Insight Pharmaceuticals (MM).
Molecular Insight Pharmaceuticals (MM) (NASDAQ:MIPI)
Gráfico Histórico do Ativo
De Nov 2023 até Nov 2024 Click aqui para mais gráficos Molecular Insight Pharmaceuticals (MM).